What Is Cagrilintide? A Research Overview of the Amylin Analogue

July 1, 2026

Cagrilintide is a synthetic, long-acting amylin analogue that functions as an amylin (and calcitonin) receptor agonist. It is designed to mimic the pancreatic peptide amylin, a molecule involved in satiety and gastric-emptying signalling. Cagrilintide is supplied strictly for research use only, and is not for human or veterinary use. This overview explains what the compound is, how amylin receptor agonism is understood, and why it has become a focus of preclinical energy-balance research.

What cagrilintide is

Cagrilintide is a synthetic peptide characterised as a long-acting amylin analogue. Native amylin (also called islet amyloid polypeptide) is a small pancreatic peptide co-secreted with insulin from the beta cells, and it participates in signalling around nutrient intake, satiety and the rate of gastric emptying. Cagrilintide is engineered to reproduce this receptor-level activity while carrying structural modifications that confer an extended half-life, improving its stability for laboratory investigation.

In supplier catalogues and the research literature, cagrilintide is grouped with the metabolic research peptides, and it is typically handled as a lyophilised (freeze-dried) powder to be reconstituted for in vitro or preclinical work. What distinguishes it from many peptides in this space is its target: rather than acting on the incretin receptors, cagrilintide is an amylin receptor agonist, engaging the amylin receptor family and the related calcitonin receptor.

All material discussed here is intended for research use only. Nothing in this article describes or implies any human or veterinary application.

How it works: amylin receptor agonism

To understand cagrilintide, it helps to understand amylin biology. Amylin is released alongside insulin in response to nutrient intake, and its signalling is associated with satiety cues and the modulation of gastric emptying in model systems. The amylin receptors are not single fixed entities: they are formed when the calcitonin receptor, a class B G-protein-coupled receptor, associates with accessory proteins known as receptor-activity-modifying proteins (RAMPs). This assembly generates the distinct amylin receptor subtypes that researchers seek to characterise.

As a long-acting amylin analogue, cagrilintide is studied for its ability to bind and activate these amylin receptors, as well as the calcitonin receptor from which they derive. Reconstituted cagrilintide is therefore commonly used in receptor-binding, signalling and related in vitro assays where amylin-pathway activity can be probed. Its extended half-life makes it a convenient tool reagent for experiments in which stability over time is an advantage.

It is important to be precise about mechanism: cagrilintide is not an incretin or GLP-1 receptor agonist. Whereas GLP-1 agonists act on the glucagon-like peptide-1 receptor within the incretin system, cagrilintide's targets sit in the amylin and calcitonin receptor family. The two act on separate, though physiologically complementary, signalling routes. This distinction is central to how the compound is classified and studied, and it is the reason cagrilintide is of interest as a probe for a pathway that incretin-focused peptides do not directly address.

Why researchers study it

Cagrilintide is of interest in preclinical research primarily as a tool for studying amylin biology and energy-balance signalling. Because amylin sits at the intersection of satiety and gastric-emptying pathways, an analogue with an extended half-life offers a stable reagent for investigating how these signals are transmitted and modulated in model systems.

A particular area of research interest is the pairing of amylin analogues with GLP-1 receptor agonists. Because amylin and GLP-1 act on distinct but potentially complementary satiety pathways, combining a compound such as cagrilintide with a GLP-1 agonist is studied as a way to probe how these routes interact at a signalling level. This is a research pairing explored in cell-based and preclinical systems, and it is valued precisely because it allows converging pathways to be dissected using well-defined reagents.

Areas where the peptide has been studied, or is of research interest, include receptor-signalling characterisation, comparative pharmacology against other metabolic peptides, and structure-activity investigations of amylin analogue design. These are questions of mechanism and molecular pharmacology. This article makes no therapeutic, clinical or weight-related claims, and none should be inferred: the value of cagrilintide in this context is as a research reagent for understanding biology.

Purity, COA and formats at Reta Research

For laboratory work, the identity and purity of a research peptide are as important as the sequence itself. Cagrilintide at Reta Research is supplied as a lyophilised powder intended for reconstitution in the laboratory, and each batch is accompanied by documentation so that researchers can verify what they are working with.

Our approach to analytical verification is described on the Quality Testing page, which outlines the methods used to assess identity and purity. A corresponding Certificate of Analysis (COA) is made available so that the reported purity and analytical results can be reviewed before material is used in any assay. Reviewing the COA against your own experimental requirements is good practice for reproducible research.

As with everything in our catalogue, cagrilintide is offered for research use only and is not for human or veterinary use.

Frequently asked questions

Is cagrilintide a GLP-1 agonist?

No. Cagrilintide is a long-acting amylin analogue that acts as an amylin (and calcitonin) receptor agonist. It is not an incretin or GLP-1 receptor agonist. Its target is the amylin receptor family, a separate signalling route from the GLP-1 receptor, although the two pathways are often studied together because they are considered complementary.

How does cagrilintide differ from semaglutide?

The two act on different receptor systems. Cagrilintide is an amylin analogue engaging the amylin and calcitonin receptors, whereas semaglutide is a GLP-1 receptor agonist that acts within the incretin system. For a fuller discussion of the GLP-1 agonist mechanism, see our overview What Is Semaglutide?. Their distinct targets are exactly why the two classes are of interest when studied in combination.

What sizes are available?

Cagrilintide is offered in several vial presentations to suit different research scales. The current formats and their specifications are listed on the Cagrilintide product page, which is kept up to date with available options.

Is it third-party tested?

Analytical verification is central to how the material is supplied. Details of the testing methodology are set out on our Quality Testing page, and a Certificate of Analysis is provided so the reported results can be reviewed prior to use.